Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06388967
Status:
RECRUITING
Last Update Posted:
2024-04-29
First Post:
2024-04-19
Brief Title:
Pancreatic Cancer Detection Consortium
Sponsor:
City of Hope Medical Center
Organization:
City of Hope Medical Center
Study Overview
Official Title:
Early Detection of Pancreatic Cancer Prospective Study
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PCDC
Brief Summary:
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma
Detailed Description:
Pancreatic ductal adenocarcinoma PDAC is one of the deadliest forms of cancer It often goes undetected until it is at an advanced stage making it challenging to treat Currently only a small percentage of patients are diagnosed early enough for effective treatment While a blood marker exists called serum carbohydrate antigen 19-9 CA19-9 it is used primarily to track the disease and it is unreliable for early detection
To address this problem the researchers have developed a new method to analyze circulating vesicles called exosomes which contain specific genetic material called microRNAs miRNAs In a previous study by analyzing both the miRNAs that circulate freely in serum and the miRNAs that are inside the exosomes the researchers have already identified a combination of 13 miRNAs that could accurately detect early-stage PDAC
In this study the researchers will test this method in a larger international cohort study This study aims to confirm the effectiveness of this approach in accurately identifying PDAC at its earliest stages
To address this problem the researchers have developed a new method to analyze circulating vesicles called exosomes which contain specific genetic material called microRNAs miRNAs In a previous study by analyzing both the miRNAs that circulate freely in serum and the miRNAs that are inside the exosomes the researchers have already identified a combination of 13 miRNAs that could accurately detect early-stage PDAC
In this study the researchers will test this method in a larger international cohort study This study aims to confirm the effectiveness of this approach in accurately identifying PDAC at its earliest stages
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None